Objectives To evaluate the effect of pharmaceutical care (PC) on glycemic control in patients with type 2 diabetes mellitus. Methods A systematic search of literature was conducted to identify randomized controlled trials (RCTs) in patients with type 2 diabetes mellitus. RCTs published in English between January 2011 and November 2015 were identified using nine electronic databases: MEDLINE, International Pharmaceutical Abstracts (IPA), EMBASE, Scopus, Science Direct, Cochrane Library, Web of Science, Springer Link, and Google Scholar. Studies were included if they outlined a pharmaceutical care intervention conducted by pharmacists alone or in collaboration with other health care professional(s). The studies were identified and data was extracted independently by two reviewers. The meta-analysis was conducted by using RevMan version 5.3. A random-effects model was used to calculate the standard mean difference (SMD) with a 95% confidence interval in glycosylated haemoglobin (HbA1 C ) levels. Key findings Thirteen RCTs outlining PC interventions in type 2 diabetes mellitus patients (n = 1828) were included. The interventions included care plan development, medication reviews, patient education and counselling of patients with follow-up. All RCTs reported statistically significant reductions in HbA1c in the intervention group (SMD = À0.97; 95% CI À1.21 to À0.73; P = 0.00001) as compared to the control group. Significant heterogeneity in SMD (v 2 = 68.96) was observed. Conclusions The findings suggest that PC interventions are effective (at least in shortterm follow-up in hospital setting) in reducing HbA1c levels in patients with type 2 diabetes mellitus. Pharmacists, working alone or in collaboration with other health professionals have significant impact on improving the health status of patients with type 2 diabetes mellitus.
Introduction
Diabetes mellitus is a major public health concern. It was identified by world leaders in the 2011 Political Declaration on the Prevention and Control of Non-communicable diseases as the one of the four major priority health conditions. It is a long-term condition associated with an higher incidence of morbidity and mortality; it has been reported that patients with diabetes mellitus have an 11 times greater morbidity than the non-diabetic population. [1] In addition, the prevalence of the condition is increasing worldwide. In 2010 global estimates reported the proportion of people with diabetes mellitus between the ages 20-79 years was 6.4%, [2] and in a World Health Organisation report on diabetes, it has been estimated that the number of patients with diabetes mellitus has doubled between 1980 and 2014.
Diabetes can be controlled by modification of lifestyle and/or through adherence to anti-diabetic medicine regimens. It has been well established that poor glycemic control leads to hospitalization, long-term complications, disease progression, premature disability and greater mortality. [3, 4] A study conducted by Statton et al. found that for every 1% decrease in glycosylated haemoglobin (HbA1 C ) there was a 37% reduction in the risk of microvascular complications, 14% for myocardial infarction and 21% in diabetes-related risk of death. [5] The role of the pharmacist has shifted over time, from product-oriented practise, to a role that has a strong involvement in patient-centred care. The provision of pharmaceutical care (PC) has been one means by which this is being achieved. PC is the responsible provision of drug therapy to patients in-order to achieve defined outcomes and to improve patient quality of life. [6] Clinical pharmacists in collaboration with patients and other health professionals design, implement and monitor pharmaceutical care plans which are intended to identify and resolve actual drugrelated problems (DRP) as well as preventing potential DRPs. [7] Studies have reported significant positive effects associated with PC as it relates to the control of HbA1 C in type 2 diabetes patients. [8, 9] There have been published systematic reviews and meta-analyses on patient adherence to anti-diabetic medications. [10, 11] Meta-analyses have also been conducted on randomized controlled trials (RCTs) published up until 2010, [12, 13] and another included RCTs through to 2011, [14] albeit the database search was limited.
The present meta-analysis was conducted to investigate an up-to-date evaluation of the effectiveness of PC on glycemic control. The objective was to report the main components of PC interventions and their impact on patient health outcomes in addition to providing an evaluation of the effect of PC on glycemic control of type 2 diabetes patients.
Methods

Search strategy
A systematic search of literature was conducted to identify RCTs published in English between January 2011 and November 2015 by using the following electronic databases: MEDLINE (Ovid SP), International Pharmaceutical Abstracts (IPA), EMBASE, Scopus, Science Direct, Cochrane Library, Web of Science, Springer Link, and Google Scholar (Check Table S1 for details). Two authors (RK and ZUB) searched following keywords 'pharmaceutical care' or 'medicine management' or 'medicine therapy assessment' or 'pharmacy services' or 'patient centered care' or 'pharmacist' or 'community pharmacist' or 'hospital pharmacist' or 'diabetes' or 'diabetes mellitus'. The search was restricted to randomized controlled trial only.
Inclusion/exclusion process
Two of the authors (RK and ZB) reviewed the titles and abstracts of all selected articles for relevance (Check Table  S1 for details). In case of any doubt regarding inclusion each full text article was reviewed for relevance. Non-randomized and secondary studies including literature reviews, systematic reviews and meta-analyses were excluded.
Data extraction and quality assessment
The following characteristics were documented for each study included in this review: authors, country, sample size, study design, study population, follow-up period, study setting, study outline (intervention provided) outcome measure and the effect of the intervention. Two reviewers (RK & ZB) extracted the data and rated the studies for quality and outcome measures. The quality of studies were evaluated according to a hierarchy of study designs reported by the Scottish Intercollegiate Guidelines Network (SIGN). [15] Quantitative data synthesis
In this meta-analysis, the authors included all those studies that reported appropriate data. The majority of studies only reported the means and standard deviations (SD) of HbA1c at baseline and at the final point, for both intervention and control groups without calculation of means and SD changes in HbA1c from baseline to the final recording. For these studies, means and SD changes from baseline to final point were calculated using the methods described in the Cochrane Handbook for Systematic Reviews of Interventions 5.0.2. [16] In this manner, the change in mean of HbA1c in each group was calculated by subtraction of the final mean value from the baseline mean value. The missing SD change in HbA1c level was substituted by an imputed value. For example, the SD change in HbA1c in intervention group was calculated using the following formula:
where, SD(C) was the SD change of HbA1c level in the intervention group, SD(B) was the SD of baseline HbA1c level in the intervention group, SD(E) was the final SD of HbA1C level in the intervention group and R was the correlation coefficient. The value of correlation coefficient (R) was calculated from one study reporting the complete data and hence was substituted into the calculation of the overall change of SD. Assuming that one study (RCT x ), included in the present meta-analysis reported the values of means and SD of HbA1C level for change and for baseline and final point and then the formula could be presented as: where, SD x (B) was the baseline SD of HbA1C level of the intervention group in RCT x , SD x (E) was the final SD of HbA1C level of the intervention group in RCT x , and SD x (C) was the SD change of HbA1C level of the intervention group in RCT x . The SD change of HbA1C level in control groups was also be calculated by using the above formulas.
In the present meta-analysis, the outcome of interest was the mean reduction in HbA1c level of the intervention and control groups over the follow-up period of the study. For the meta-analysis of continuous data, standard mean difference (SMD) the estimated confidence intervals (CIs) for SMD were 95%. The chi-square (v 2 ) test was used to evaluate the heterogeneity between the included studies. A P value ≤0.1 was considered as statistically significant. In the presence of heterogeneity (P value ≤0.1), the outcomes were combined by using a random-effect model whereas in the absence of heterogeneity (P value ≥0.1), outcomes were combined by using the fixed-effect model. Visual inspection of funnel plot of SMD against standard error (SE) was used to identify the publication bias. Asymmetry of funnel plot was tested by Egger's test (P value ≤0.05 was statistical significant). Statistical analysis was performed by using Review Manager (version 5.3).
Results
Selection and characteristics of studies
The literature search identified 1989 titles/abstracts and those containing key terms were selected (n = 291). A total of 205 studies were found after removing duplicates. Thirteen randomized controlled trials (RCTs) fulfilled the inclusion and exclusion criteria of study and were included in this meta-analysis.
The studies were conducted in USA, [17] UK, [18] Belgium, [19] Brazil, [20] Jordan, [21] Taiwan, [22] Iraq, [23] Iran, [24] India, [25] China, [26, 27] and Malaysia. [28, 29] Figure 1 depicts the study selection conducted according to the PRISMA (Preferred reporting items for systematic reviews and metaanalyses) Statement.
From the 13 trials, eleven RCTs were conducted at a single centre (hospitals or clinic) while two were multicentre studies (community pharmacies). Seven RCTs included follow-up period of ≤6 months, the remainder being >6 months. The total patient sample across all the studies was 1828. All 13 RCTs included type 2 diabetes mellitus patients. Eleven of the 13 RCTs reported the age of patients and only included adults. The basic characteristics of the studies included are summarized in Table 1 .
Methodological quality of included studies
The methodological quality of the included RCTs was variable. Allocation concealment from the patients was not feasible; therefore, RCTs have not properly described how they address the allocation concealment. Due to the nature of pharmaceutical care interventions, the majority of the RCTs were not completely blinded. Two RCTs were assigned 1++, six RCTs as 1+ and five RCTs were assigned 1À. These scores are listed in Table 1 .
Types of interventions included
The basic components of the interventions are summarized in Table 2 . Eleven studies included interventions provided by clinical pharmacists in the hospital setting and two studies involved service provision via community pharmacists. Four RCTs described the training pharmacists received including an 8-h diabetes training programme, ambulatory care training, training session on pathophysiology of T2DM and pharmacological and non-pharmacological management and certified diabetes education. The basic components of interventions included: care plan development, medication review, patient education and counselling regarding diabetes, its complications, medications, life-style modification, exercise and self-monitoring. In some studies, patients received verbal as well as written information. Almost all RCTs included patient-pharmacist's face-to-face interviews however, some studies also included follow-up telephone calls along with patient visits to the study site.
Impact of pharmacists' interventions on change in HbA1c level
Ten RCTs reported change in HbA1 c level as the primary clinical outcome and in three RCTs it was the secondary clinical outcome. Two RCTs reported mean and SD changes of HbA1c level from baseline to final point for both groups. Eleven RCTs included the means (and SD) of HbA1 c levels for both groups at baseline and final point. For these studies, the mean (and SD) changes of HbA1c levels were calculated for both groups by using an imputed value. Differences in changes of HbA1c between intervention and control groups are summarized for each study in Table 3 .
All RCTs have shown statistically significant reductions in HbA1c level. This showed that pharmacists' interventions led to an improved glycemic control as compared to control group. There was significant heterogeneity of SMD (v 2 = 68.96: df = 12; P = 0.00001). Thus, the random effect (RE) model was used to combine the outcomes. The pooled estimate of 13 trials presented a statistically significant reduction in HbA1c for intervention group patients in comparison to control group patients. The SMD and 95% CIs for 13 RCTs analysed are presented as a forest plot in Figure 2 . The present study reported a statistically significant difference in pooled effect size that favoured the pharmaceutical care group over the control group (SMD = À0.97; 95% CI À1.21 to À0.73; z = 7.87; P = 0.00001).
Potential publication bias
Publication bias (also known as reporting bias) was evaluated by creating a Begg-Mazumdar's funnel plot (Figure 3) . The results did not show any publication bias in the studies.
Discussion
Glycemic control represented by HbA1c, is an important test for the measurement of effective blood glucose control in diabetic patients over time. The aim of the present metaanalysis was to collect and quantitatively analyze HbA1c data from RCTs that implemented a pharmaceutical care intervention that involved a pharmacist. The results of this analysis would therefore provide evidence as to whether pharmaceutical care interventions were effective in reducing HbA1c levels in patients with diabetes type 2 and what these interventions were. The findings of this meta-analysis report a statistically significant reduction in the HbA1c level i.e. ≥0.50% in the pharmaceutical care intervention group as compared to controls. These results are consistent with the findings of an earlier meta-analysis demonstrating significant improvements in diabetic patients receiving pharmaceutical care. [12, 30] It would appear that the effects of the pharmaceutical care model have been sustainable over time.
The components of pharmaceutical care which were most commonly implemented included: care plan development, medication review, patient education (via verbal and written information) and counselling regarding diabetes, its complications, medications, life-style modification, exercise and self-monitoring. Randomized controlled trials with patient education relating to self-monitoring and self-management of diabetes reported statistically significant improvements in glycosylated haemoglobin levels. These findings provided the evidence for the effective role of pharmacists in patient education and counselling. Our findings are supported by a previous meta-analysis (that included studies published prior to 1999), that reported effective patient education led to statistically significant improvement in glycemic control. [31] Four RCTs included interventions conducted by welltrained pharmacists reporting statistically significant decreases in HbA1c levels in the intervention group compared with the control group. These findings highlight the importance of well-trained pharmacists for successful implementation of PC and for improving the patient outcomes. The present study findings are in line with a previous systematic review showing the improved outcomes resulted from the interventions conducted by well-trained interventionists (pharmacists). [32] The emergence of clinical pharmacy services is at early stages of development in some developing countries. In the present meta-analysis, except for three RCTs (US, UK, Belgium) all the others were conducted in developing countries (Brazil, China, Jordan, India, Iran, Iraq, Malaysia and Taiwan). Type 2 diabetes has become a major health problem in developing countries; therefore, strategies are required for treatment as well as prevention of this condition. The findings from a recent systematic review and meta-analysis provided the evidence for the effectiveness of different strategies in type 2 diabetes mellitus prevention. [33] Figure 1 Study selection process. A meta-analysis of Randomized controlled trials Zaheer Ud-Din Babar et al. [25] À1.71 AE 0.5 60 À0.72 AE 0.39 60 Figure 2 Forest plot of HbA1c change between intervention group and control group (effective size). Figure 3 Funnel plot of standard error against standard mean difference (SMD).
The present systematic review showed that RCTs with follow-up of >6 months report more significant mean reductions in HbA1c levels than RCTs with shorter follow-up. This suggests that better control is afforded through sustained PC interventions. The present study supports the previous meta-analysis in reporting a high mean reduction in glycosylated haemoglobin level resulting from longer follow-up. [13] Implications for practise
The main aim of this study was to evaluate the effect of pharmaceutical care on glycemic control in patients with type 2 diabetes mellitus. We have done so by systematically searching and reporting on the outcome of pharmaceutical care in the management of type 2 diabetes, with special attention to the effect of pharmacists' interventions. Our findings suggest that globally, there is great variability in the use of pharmaceutical care for achieving clinical outcomes (e.g. glycemic control). Published RCTs have clearly demonstrated that pharmaceutical care interventions are effective in glycemic control in type 2 diabetes mellitus patients. The literature also shows that pharmacists have specific set of skills, strategies, and practises related to medicines use and this sets apart the work of the pharmacist from other members of the healthcare team. The data also suggest the description of the interventions regarding how to develop and support the patient-centred activities in the management of type 2 diabetes.
Limitations
The present meta-analysis has limitations based on the reporting bias in some of the RCTs that may be due to the reporting of the desired outcome (reduction in HbA1c) as a secondary outcome measure. Furthermore, there is heterogeneity in the studies including; smaller study sample size, shorter follow-up time period and study setting.
This study quantitatively analyses only RCTs and excludes all other interventional studies including; nonRCTs, cohort and pre-post studies to minimize the selection bias of patients. Additionally, the present study includes only patients diagnosed with type 2 diabetes mellitus to minimize the heterogeneity of the patient population. The results cannot be generalized to community pharmacies as most the clinical trials included were performed in hospitals or clinics. Future research is needed with pharmaceutical care conducted by well-trained pharmacists with longer term follow-up.
Conclusion
Quantitative analysis of the collective literature suggests that pharmaceutical care interventions are effective (at least in short-term follow-up in hospital setting) in reducing HbA1c levels in type 2 diabetes mellitus patients. Pharmacists working alone or in collaboration with other health professionals have a significant impact on improving the health status of patients with type 2 diabetes mellitus.
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